BANK VONTOBEL/PUT/NOVO NORDISK ADR B/100/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 14:03:15 2024-05-31 EDT | ||
| 0.048 EUR | -4.00% |
|
| 1 month | -68.21% | ||
| 3 months | -84.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 0.048 | -4.00% |
| 24-05-30 | 0.05 | -9.09% |
| 24-05-29 | 0.055 | +3.77% |
| 24-05-28 | 0.053 | -.--% |
| 24-05-27 | 0.053 | +20.45% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 02:03 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM384X |
| ISIN | DE000VM384X0 |
| Date issued | 2023-10-19 |
| Strike | 100 $ |
| Maturity | 2024-09-20 (110 Days) |
| Parity | 10 : 1 |
| Emission price | 1.08 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.37 € |
|---|---|
| Lowest since issue | 0.044 € |
| Spread | 0.01 € |
| Spread % | 18.87% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Warrants
- Warrant
